$SVSN Extremely undervalued #cannabis #medical #marijuana #mmj #hemp stock price

$SVSN majority owned Florida medical #marijuana clinic and #hemp company #MediCannaVision Inc., dba #CannaVision. http://cannavisionclinics.com #cannabis Extremely undervalued market cap $15.7M (imo)


Dr.M.Sheldon_Polsky_Signed-to-HeadUp-CannaVision’s-Bay-Pines-Medical-Cannabis-and-Pain-Management-Clinic in St Pete, Florida Press Release Jan 11 2018 https://www.otcmarkets.com/stock/SVSN/news/Dr–M–Sheldon-Polsky-Signed-to-Head-Up-CannaVision%E2%80%99s-Bay-Pines-Medical-Cannabis-and-Pain-Management-Clinic-in-St-Pete–Florida?id=180145&b=y

601 E. Charleston Boulevard Studio 100 Las Vegas, NV 89104
Phone: 818-326-6018 Fax: 818-304-0578
Dr. M. Sheldon Polsky Signed to Head Up CannaVision’s Bay Pines
Medical Cannabis and Pain Management Clinic in St Pete, Florida
LAS VEGAS, NEVADA (OTCMarkets-1/11/2018) StereoVision Entertainment, Inc.
(OTC PINK: SVSN), a publicly traded Nevada corporation announced today that
they’re marjority owned Florida medical cannabis and industrial hemp company
CannaVision has signed Dr. M. Sheldon Polsky M.D. to head up their next medical
marijuana and holistic pain management clinic at 9709 Bay Pines Boulevard St
Petersburg, Florida.
“With our advocating for veterans use of medical marijuana, Dr Poksky, having
been honorably discharged from the Army and then retiring from the Air Force
Reserve as a Full Bird Colonel, is a terrific selection to head up our Bay Pines
Medical Cannabis and Holistic Pain Management Clnic,” said CannaVision’s Chief
Operating Officer, Steven Previch. “Actually, just a few years ago, Dr. Polsky was
a staff physian at the Bay Pine VA Medical Center across the street from our Bay
Pines clinic. During Dr. Polsky’s military service he was awarded the Army
Commnedation Medal and the Air Force Meritorious Service Medal. While, due to
the mistakes in the medical marijuana legislation made by the Florida legislature
that attorney John Morgan has filed a lawsuit to correct, and the bureaucratic red
tape that’s caused a slow start to patients applying for medical marijuana cards,
some medical marijuana clinics are closing. We’re staying true to our clinic’s core
mission of treating veterans and civilians with qualifying conditions such as
PTSD and opioid addiction from chronic pain, and cancer patients, with medical
marijuana. And we will be here for the expontial growth we believe is coming
when the bugs are worked out of the system. Going forward CannaVision Cinics
will also be expanding our variety of treatments for holistic pain management.”
StereoVision Entertainment Inc. http://stereovision.com HQ’d in Las Vegas, Nevada
StereoVision is a publicly traded Nevada corporation (OTC:SVSN) focused on
creating, acquiring, and producing multimedia content with its media
subsidiaries, the wholly owned 9 time Emmy Award-winning production company
REZN8, http://rezn8.com, the majority-owned family entertainment company,
Inspirational Vision Media, Inc. http://ivmi.biz, and the majority-owned medical
cannabis clinic and industrial hemp Florida C corporation MediCannaVision Inc.,
dba CannaVision. http://cannavisionclinics.com
Safe Harbor Statement: Except for historical information certain statements in
this news release may contain forward-looking information within the meaning of
601 E. Charleston Boulevard Studio 100 Las Vegas, NV 89104
Phone: 818-326-6018 Fax: 818-304-0578
Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and those statements are subject to the safe harbor
created by those rules. All statements, other than statements of fact, included in
this release, including, without limitation, statements regarding potential plans
and objectives of the Company, are forward-looking statements that involve risks
and uncertainties. There can be no assurance that such statements will prove to
be accurate and actual results and future events could differ materially from
those anticipated in such statements. The Company cautions that these forwardlooking
statements are qualified by other factors. The Company undertakes no
obligation to publicly update any statements in this release.
Contact: Steven Previch 305-972-1030 Steven@cannavisionclinics.com



Email Update from Jack Honour CEO/President! CannaVision dividend shares

Hi xxxxxxxxx,

Appreciate your investment and your support. Have lots of things brewing right now. Here’s today’s news. http://stereovision.com/pdf/CV-Polsky-PR.pdf Keep an eye on us, We expect 2018 to be a breakout year for SVSN.

All the Best,

Jack Honour
O 818-326-6018
C 818-456-3858
j <honourjack@gmail.com>ack@stereovision.com
twitter.com – JackHonour1
linkedin.com – Jack Honour

On Tue, Jan 9, 2018 at 7:56 AM, xxxxxxxxxxxxx wrote:

> Good morning Jack,
> I’m just wondering if the company will be putting out a company update to the market anytime soon? ‘Tis the season? Do you have any updates for investors like me?
> Thanks again,
> xxxxxxxxx
> On Fri, Sep 22, 2017 at 8:43 AM, Jack Honour <honourjack@gmail.com> wrote:
>> Hi xxxxxxx, per the news release (http://www.marketwired.com/press-release/stereovision-extends-shareholder-record-date-special-dividend-cannavisions-pinksheets-svsn-2214397.htm) the CannaVision dividend shares will be distributed on a pro rata basis “upon an effective registration statement”. We have just funded the substantial cost of filing the S-1 with the SEC and I expect an effective registration statement is at least 120 days away. Regards, Jack Honour
>> Jack Honour
>> CEO/President
>> StereoVision
>> O 818-326-6018 <(818)%20326-6018>
>> C 818-456-3858 <(818)%20456-3858>
>> http://stereovision.com
>> j <honourjack@gmail.com>ack@stereovision.com
>> facebook.com/TeamS3D
>> twitter.com – JackHonour1
>> linkedin.com – Jack Honour


See you at $2.50 price per share (imo of course).



is @Carl_C_Icahn $VLTC about to get @ShortSqueezed1

UPDATE from December 18 2017: ICAHN CARL C 52% owner of $VLTC, adds more to his insider share ownership.


3 year weekly chart could have put in the bottom now… it has 10 bagger potential with a current market cap of only 5.8 Million!

It would take 27 days for all the short sellers to cover their position, could make for one really strong short squeeze.

$VLTC 10-Q Sept 30, 2017, items that stood out for me…

Voltari Corporation
Notes to Condensed Consolidated Financial Statements

3. Real Estate Investments

During 2015 and 2016 we acquired two real estate properties, one located in Long Branch, NJ and the other in Flanders, NY.


5. Revolving Note

On August 7, 2015, we, as borrower, and Koala Holding LP (“Koala”), as lender, an affiliate of Carl C. Icahn, our controlling stockholder, entered into a revolving note (the “Prior Note”). Pursuant to the Prior Note, Koala made available to us a revolving loan facility of up to $10 million in aggregate principal amount. Borrowings under the Prior Note bore interest at a rate equal to the greater of the LIBOR rate plus 350 basis points, per annum, and 3.75%, per annum. The Prior Note also included a fee of 0.25%, per annum, on undrawn amounts and matured on the earliest of (i) December 31, 2017, (ii) the date on which any financing transaction, whether debt or equity, was consummated by us (or our successors and assigns) with net proceeds in an amount equal to or greater than $10 million, and (iii) at our option, a date selected by us that was earlier than December 31, 2017. Subject to the terms and conditions of the Prior Note, we could repay all or any portion of the amounts outstanding under the Prior Note at any time without premium or penalty, and any amounts so repaid would, until the maturity date, be available for re-borrowing. As collateral for the Prior Note, we pledged and granted to Koala a lien on our limited liability company interest in Voltari Real Estate Holding LLC (“Voltari Holding”). As of March 29, 2017, borrowings on this facility totaled $5.0 million.

On March 29, 2017, we and Koala amended and restated the Prior Note (the “Amended Note”). Pursuant to the Amended Note, Koala made available to the Company a revolving loan facility of up to $30 million in aggregate principal amount (the “Commitment”). The Company may, by written notice to Koala, request that the Commitment be increased (the “Increased Commitment”), provided that the aggregate amount of all borrowings, plus availability under the aggregate Increased Commitment, shall not exceed $80 million. Koala has no obligation to provide any Increased Commitment and may refuse to do so in its sole discretion. The Amended Note provides that the net proceeds thereunder in excess of $10 million will be used by the Company for the acquisition, improvement, development, modification, alteration, repair, maintenance, financing or leasing of real property, including any fees and expenses associated with such activities. Borrowings under the Amended Note will bear interest at a rate equal to the LIBOR Rate (as defined in the Amended Note) plus 200 basis points, per annum, subject to a maximum rate of interest of 3.75%, per annum. The Amended Note matures on the earliest of (i) December 31, 2020, (ii) the date on which any financing transaction, whether debt or equity, is consummated by the Company (or its successors and assigns) with net proceeds in an amount equal to or greater than $30 million, and (iii) at the Company’s option, a date selected by the Company that is earlier than December 31, 2020 (the “Maturity Date”). The Amended Note also allows the Company to, upon written notice to Koala not more than 60 days and not less than 30 days prior to the Maturity Date, request that Koala extend the Maturity Date to December 31, 2022. Koala may, in its sole discretion, agree to extend the Maturity Date by providing written notice to the Company on or before the date that is 20 days prior to the Maturity Date.

As of September 30, 2017, borrowings under the Amended Note equaled $5.5 million. The outstanding balance, including interest of $0.3 million, totaled $5.8 million.


As of September 30, 2017, our Series J preferred stock had an aggregate redemption value of approximately $55.4 million, including paid-in-kind dividends of $24.4 million and accrued dividends of $1.8 million. We recorded accretion associated with our Series J preferred stock of $0.7 million and $0.6 million for the nine months ended September 30, 2017 and 2016, respectively.

In connection with the closing of our rights offering on March 30, 2015 , entities affiliated with Mr. Carl C. Icahn, our largest shareholder, became the owner of approximately 52.3% of our common stock, which resulted in a change of control of the Company. This constituted a redemption event pursuant to the terms and conditions of the Series J preferred stock, and as a result each holder of shares of Series J preferred stock had the right to require the Company to redeem all or a portion of such holder’s shares of Series J preferred stock. Entities affiliated with Mr. Carl C. Icahn waived their option to redeem Series J preferred stock in connection with the change in control resulting from the completion of the rights offering that closed on March 30, 2015. On April 13, 2015, we redeemed 29,316 shares of Series J preferred stock for approximately $1.0 million in cash from holders not affiliated with Mr. Carl C. Icahn. Following the April 13, 2015 redemption of Series J preferred stock, entities affiliated with Mr. Carl C. Icahn became the owner of approximately 97.9% of our Series J preferred stock.


7. Liquidity and Capital Resources

Our principal needs for liquidity since we began executing our transformation plan in August, 2015, have been to fund operating losses, working capital requirements, capital expenditures, restructuring expenses, acquisitions and integration and debt service. Our principal sources of liquidity as of September 30, 2017, consisted of cash and cash equivalents of $0.6 million, and our ability to borrow on our Amended Note . See Note 5, Revolving Note, of our condensed consolidated financial statements for more information.

10. Subsequent Events

On October 11, 2017, the Warrants to purchase 1,014,958 shares of common stock, expired without any such Warrants being exercised.

Any future acquisitions are intended to be initially financed through borrowings available under our Amended Note (as defined herein) with Koala Holding LP (“Koala”).

Real Property Acquisitions —In connection with the execution of our transformation plan, on September 17, 2015, we acquired a real estate parcel in Long Branch, New Jersey. The property is subject to a triple net lease with JPMorgan Chase Bank, N.A. (“Chase”), the original term of which expires in June, 2020 (with two, five-year renewal options), pursuant to which Chase is responsible for the payment of basic rent as well as the payment of real estate taxes, maintenance costs, utilities, tenant’s insurance and other property related costs. Refer to http://investor.shareholder.com/jpmorganchase/sec.cfm for the financial statements of the tenant. The purchase price was approximately $3.63 million. As of September 30, 2017, the average annual rental income for the property over the remaining term of the original lease is approximately $203,000.

On May 18, 2016, we acquired a real estate parcel in Flanders, New York. The property is subject to a lease with 7-Eleven, Inc. (“7-Eleven”), the original term (the “Original Term”) of which expires in December 2029 (with four, five-year renewal options (the “Renewal Term,” and together with the Original Term, the “Term”)). During the Term, 7-Eleven is responsible for the payment of basic rent, as well as the payment of, subject to certain exceptions, real estate taxes, utilities, tenant’s insurance and other property related costs. The landlord is responsible for certain maintenance and repair costs. The purchase price was approximately $2.82 million. As of September 30, 2017, the average annual rental income for the property over the remaining Original Term is approximately $163,000.


Revenue for the nine months ended September 30, 2017 increased $61 thousand as a result of the addition of the Flanders property in May, 2016.

General and administrative, excluding depreciation

For the three months ended September 30, 2017, general and administrative expense, excluding depreciation, declined by approximately $0.3 million from the three months ended September 30, 2016, due to a:

– $0.1 million decrease in personnel costs; and

– $0.2 million decrease in various other administrative costs.

For the nine months ended September 30, 2017, general and administrative expense, excluding depreciation, declined by approximately $1.0 million from the nine months ended September 30, 2016, due to a:

– $0.4 million decrease in personnel costs, resulting from January 2016 staff reductions, as well as staff reductions in connection with our transformation plan;

– $0.5 million decrease in accounting, legal and professional fees resulting from the execution of our transformation plan and acquisition of the Flanders property and completion of our IRS audit; and

– $0.1 million reduction in various other administrative costs.

$ALRT #tape #reading for #Pennystock #Daytraders 09-19-2017

September 19, 2017 – 10:02 AM EDT
FDA Grants ALRT Clearance for Insulin Dose Adjustment (IDA) Feature

IDA is designed to ensure that patients get an effective and timely insulin dose(s) based on accurate data about their specific needs

RICHMOND, VA–(Marketwired – September 19, 2017) – The United States Food and Drug Administration (FDA) has granted clearance to ALR Technologies Inc. (OTCQB: ALRT) for an innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system.

The ALRT system with IDA uses the American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) insulin dosing guidelines to process patient blood glucose values to provide reference doses based on the guidelines. The reference doses are compared with the patient’s current insulin dose(s) to determine whether current insulin dosing is optimal. If there is a difference between the patient’s current insulin dose(s) and the reference doses, this difference will be flagged and a notification sent to the managing healthcare provider (HCP) suggesting an insulin dose review. The blood glucose values are uploaded directly from the patient’s blood glucose meter.

“With FDA clearance for Insulin Dose Adjustment, it will simplify insulin dosing for healthcare providers,” said Sidney Chan CEO of ALR Technologies. “First, it makes it easy for healthcare providers to titrate insulin dosing for new insulin patients. Second, it will help healthcare providers to prescribe optimal dose(s) for patients on insulin, addressing the so called ‘insulin glass ceiling’. IDA is designed to ensure that patients get an effective and timely dose based on accurate data about their specific needs,” said Chan. Insulin manufacturer Novo Nordisk estimates that morbidity and mortality rates resulting from medication errors add an estimated $1,900 per patient to total U.S. health care costs and remember, about half of that is mistakes with insulin.1

The IDA feature is intended only for insulin-requiring Type 2 diabetes patients to provide the HCP with two reference doses. IDA is not indicated for patients who utilize insulin pumps and it is limited to adults with Type 2 diabetes on fixed dose regimen of insulin.

About ALR Technologies Inc.
ALR Technologies is a medical device company providing an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters. The System processes and streamlines collected data to support clinicians and caregivers to improve patient outcomes and assist health plans to optimize their investments in chronic disease care. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.

1 http://www.diabetesincontrol.com/a-review-of-insulin-errors/

Ken Robulak:
email: info@alrt.com

Source: Marketwired (September 19, 2017 – 10:02 AM EDT)
News by QuoteMedia

$LEXG indicates new warrant prices 300% ($0.0021) & 400% ($0.0028) ABOVE today’s market price $0.0007

At the time of this news release today, LEXG has had a trading range of 0.0006 to 0.0009 with the VWAP of $0.00073 on 91,212,877 shares traded.  So in today’s PR when the company announced reducing conversion discount by 50% and in consideration of the significant reduction in debt, each fund will receive two new warrants, which will have a conversion mechanism 300% and 400% above today’s market price!  So a simple calculation would suggest that the conversion prices are equal to $0.0021 (0.0007 x 300%) and $0.0028 (0.0007 x 400%).  What this tells me is that LEXG will need to trade at or above 0.0021 and 0.0028 in order for the debt holders to begin converting their debt into shares.  At today’s market price of $0.0007, I think that we are in for a good ride to the upside!  I have written about $LEXG in the past being a potential 10 bagger stock investment potential, and I still believe this to be true.


Here is the official PRESS RELEASE:

Lithium Exploration Group Announces 50% Reduction in Conversion Feature of Existing Debt Eliminating More Than Four Billion Shares of Dilution

Published: Aug 7, 2017 12:00 p.m. ET

PHOENIX, August 7, 2017 /PRNewswire via COMTEX/ — PHOENIX, August 7, 2017 /PRNewswire/

Lithium Exploration Group Inc. (USOTC: LEXG) announced today that it has come to terms with two major debt holders to restructure all of their convertible notes, reducing conversion discount by 50%. In consideration of the significant reduction in debt, each fund will receive two new warrants, which will have a conversion mechanism 300% and 400% above today’s market price. The collective view of the company and the debt holders is that Lithium Exploration Group is in a significantly better position than it has been in the past and the heavily dilutive terms of the debt were not sustainable for the company or its shareholders.

“This is exciting news and should show everyone the level of confidence that the debt holders have in the company’s current position,” commented CEO, Alex Walsh. “They have conceded a significant portion of their debt rights in return for warrants that produce a significant incentive to see long-term price appreciation in the LEXG security. This restructuring truly has all parties incentivized in the same direction and should show significant benefit to our existing shareholders for a long time to come.”

About Lithium Exploration Group

Lithium Exploration Group is a US-based exploration and development company focused on the acquisition and development potential of lithium brines and other precious metals that demonstrate high probability for near-term production. Currently the company is focused on testing the Sonic Cavitation Ltd. technology and the acquisition of oil and gas related assets in the US and Canada. Lithium Exploration Group is traded on the OTC Markets under the symbol LEXG.

Website: http://www.lithiumexplorationgroup.com.

Safe Harbor Statement

This news release contains “forward-looking statements”. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future testing of the ultrasonic technology.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of lithium prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact InfoShanon Chilson +1-480-641-4790 info@lithiumexplorationgroup.com

SOURCE Lithium Exploration Group Inc.

Copyright (C) 2017 PR Newswire. All rights reserved


#10Bagger Potential #Penny #Stock #Chart #Oil Industry

Due to the bad oil market in the past years, this individual oil stock has fell off the radar from the majority of retail traders. This play is still early, and the crowd doesn’t know about it yet. However, that said, there isn’t too much time left to get into this one before it moves much higher on what will likely be a very fast breakout move towards $0.20 per share. My 1st target is $0.20, although looking at the 5 year chart, I can see it moving all the way to $2.00 per share eventually.  This company is currently trading with a 1 million market cap.  Investors getting into this chart here, are looking at an easy multi-bagger opportunity in the recovering oil industry. Let me know if you want to know the stock ticker of this chart. Follow me on twitter @DazeTrader and send me a direct message.


$ACOL 100x return on investment. #100bagger #pennystock

What are some of the ingredients to find a penny stock that will give you a multi-bagger return on investment? Do you know anyone who was invested in this penny stock and made a multi-bagger return on investment?  Leave a comment at the bottom of this blog post or reply on my twitter @dazetrader www.twitter.com/dazetrader


$BRKO – I made a 13 bagger #10bagger #investment

Bought on Sept 19 2016: 300 shares at $0.05

Sold on Nov 15 2016: 300 shares at $0.70

I turned $15 into $210.

Depth/Level II for Broke Out Inc (BRKO)
$ 0.70 RT 0.00 (0.00%) Volume: 0 10:50 AM EST Nov 15, 2016
Level II
Level II Quotebook
Time MMID Size Bid
Level 2 is only
available in Real-Time
Ask Size MMID Time
Level 2 is only
available in Real-Time
Time & Sales RT
Price Size Mkt Time
$0.70 300 OTO 11/15
$0.95 70 OTO 11/08
$0.74 130 OTO 11/08
$0.65 30 OTO 11/03
$0.75 100 OTO 11/03
$0.75 400 OTO 11/03
$0.75 826 OTO 11/01
$0.80 100 OTO 10/18
$0.80 1,919 OTO 10/18
$0.50 500 OTO 10/18
$0.30 95 OTO 10/12
$0.30 0 OTO 10/12
$0.30 50 OTO 10/11
$0.25 50 OTO 10/07
$0.30 200 OTO 10/07
$0.30 200 OTO 10/07
$0.30 150 OTO 10/07
$0.30 562 OTO 10/05
$0.99 100 OTO 10/04
$0.30 77 OTO 10/04
$0.07 300 OTO 09/30
$0.11 5 OTO 09/29
$0.07 40 OTO 09/22
$0.09 1,000 OTO 09/20
$0.05 1,000 OTO 09/19
$0.08 5 OTO 09/16
$0.06 2 OTO 09/13
$0.08 100 OTO 09/08
$0.06 8 OTO 08/31
$0.061 3,000 OTO 08/29

$GOFF THC Therapeutics, leading technology company in the legal #Cannabis industry

CEO of GOFF, Brandon Romanek, ‏said this on Oct 14 2016: THC Therapeutics will be a thriving publicly traded company. PR will come & when I am able to comment I for sure will. $GOFF has had no PR.

Business Description: THC Therapeutics, Inc. is a leading technology company in the legal Cannabis industry, headquartered in Las Vegas, NV. The Company’s initial product is the dual-purpose, patent-pending dHydronator (TM) with SanitiZen (TM) technology. This device dehydrates and sanitizes. Its principal application is the expeditious dehydration of cannabis and home grown herbs. The Company plans to expand its dHydronator (TM) line with various sizes aimed at both personal and commercial applications in the near future. Currently, the most popular way to dry cannabis can take ten to 14 days. This traditional process is far too time consuming. Our product reduces that time from weeks to hours. The sanitation technology works on anything put in the chamber. Eliminating most bacteria, germs, dust mites and surface mold. Our company plans to actively seek opportunities to expand within the Cannabis industry, and alternative healthcare.

The following SEC 15-12G filing received on Jun 29, 2016 means that the company will not get suspended for not having filed recent financial statements about the company.  In other words, the stock shouldn’t get halted for not keeping their 10Q and 10K current.  http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11464552

I like the long term chart, if one can purchase the shares cheap enough, it could make for a potential 10 bagger.

$GOFF monthly-chart-10-16-2016
$GOFF monthly-chart-10-16-2016

$NVAX charts & options market analysis, suggests the majority didn’t anticipate stock price below $4.00 per share.

NVAX: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults

After Hours Quote: $ 1.38 -$6.96 (-83.45%) due to news.  Obviously “bad news” ….. i guess… as per the market’s reaction, but for the stock to drop 87% ?!?  I bought some shares at $1.35 in after hours market. Trading in the stock closed at $8.34 today in regular hours and closed at $1.40 after hours.

All-time data, monthly chart below. Note the 52 Week Range: $4.075 to $10.70.



Below is a 1 year daily chart where you can see the drop from $8.34 down to $1.40.  I also have plotted the option implied volatility which you can plainly see a run-up from mid July 2016 95% to current date Sept 15 where it peaked at 248%.   The higher the implied volatility, the higher the cost of the options.  I also added the option open interest which plots the call and put open interest in the $NVAX options market.

$NVAX Daily chart 09-15-2016
$NVAX Daily chart 09-15-2016

In addition, here is the historical and implied volatility from the OIC.


Today there was a total of 18,524 options that were traded before $NVAX distributed their news.  A total of 9,435 calls vs 9,089 puts making the put/call ratio a balanced 0.963.  The majority of today’s options volume came from the October expiration, and secondly the September contract.


An interesting point I will make is that it looks as if the NVAX market was not expecting the stock price to drop this far!  If you notice there is hardly any options traded below the $4 strike PUT contract, in other words nobody was interested in buying downside protection or insurance in fear of a downside move in the stock price.  I’ve outlined a red rectangle around the option strikes that had the most trading activity today to make it easier to follow.  Basically you can see that nobody thought NVAX was going to plunge the way it did today.


Below is the NVAX option time & sales showing the largest option trades that occurred today, along with the last 15 minutes of option trades before the close.


The final chart is a 3 minute chart plotting the after hours trading activity.